The effect of semaglutide [amount hidden] once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

What Was Tested

Researchers studied Semaglutide in this randomized controlled trial publication.

Who Took Part

The abstract describes 72 adults taking part.

By PubMed's age tags, the people studied were adults.

Participant-reported appetite ratings and Control of Eating Questionnaire (CoEQ) responses were assessed, and energy intake was measured during ad libitum lunch.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the adults nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

The Semaglutide group and the comparison group ran side by side rather than switching.

Gastric emptying was assessed using paracetamol absorption following a standardized breakfast.

What Was Measured

Topics PubMed links to this paper include Appetite, Energy Intake, Gastric Emptying, Glucagon-Like Peptides, Obesity and Semaglutide.

The authors tagged it with the keywords GLP-1 analogue, control of eating, food craving, glucagon-like peptide-1 and randomized trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 72 adults.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page.